Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGND | CLUSTER | neutral | 4/10 | CFO Octavio Espinoza and Director Jason Haas executed a cluster of derivative exercises and open-market sales on August | Aug 14, 2026 |
| GILD | COURT-RULING | bullish | 6/10 | The Fourth Circuit affirmed a district court's preliminary injunction barring Meritain Health, ProAct, and a group of al | Aug 14, 2026 |
| ATNM | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 14, 2026 |
| IFRX | 424B5 | bearish | 5/10 | InflaRx N.V. filed a 424B5 prospectus supplement to register up to $65 million in ordinary shares for an at-the-market o | Aug 14, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Twist Bioscience CEO Emily Leproust sold $14.2M of stock via a derivative exercise-and-sell transaction, while two direc | Aug 14, 2026 |
| VVOS | PRESS-RELEASE | bearish | 5/10 | Vivos Therapeutics reported Q2 2026 revenue of $5.2M, up 35% YoY but below the $5.8M consensus. GAAP EPS was -$0.31, bea | Aug 14, 2026 |
| TRAW | PRESS-RELEASE | bearish | 5/10 | Traws Pharma reported a Q2 2026 EPS of -$0.53, missing the consensus estimate of -$0.45 by 17.8%. The company had zero r | Aug 14, 2026 |
| ENVB | 8-K | bearish | 6/10 | Enveric Biosciences reported a Q2 2026 net loss of $3.0M ($0.76 per share), wider than the $2.5M loss in Q2 2025, but th | Aug 14, 2026 |
| CUE | PRESS-RELEASE | neutral | 4/10 | Cue Biopharma reported Q2 2026 net loss of $153.1M on revenue of $7.9M, well above consensus estimates on both lines, bu | Aug 14, 2026 |
| SXTP | PRESS-RELEASE | bearish | 5/10 | Sixty Degrees Pharmaceuticals reported Q2 2026 revenue of $208K (up 106% YoY) but a net loss of $2.40M ($0.90/share), mi | Aug 14, 2026 |
| BAK | 6-K | mixed | 6/10 | Braskem reported Q2 2026 consolidated recurring EBITDA of US$1,043 million, a dramatic improvement from US$192 million i | Aug 14, 2026 |
| HCWB | 8-K | bearish | 6/10 | HCW Biologics reported Q2 2026 revenue of $135,568, a significant drop from $6.5M in Q1 2026 (which included a large lic | Aug 14, 2026 |
| HCWB | PRESS-RELEASE | bearish | 8/10 | HCW Biologics reported Q1 2026 EPS of $2.22, a 212.1% beat vs the -$1.98 consensus, but this is entirely due to a previo | Aug 14, 2026 |
| EMMA | 8-K | mixed | 5/10 | Emmaus Life Sciences reported Q2 2026 net revenues of $6.3M, a 124% increase YoY, driven by recognizing upfront revenue | Aug 14, 2026 |
| HCWB | 10-Q/A | bearish | 8/10 | Analysis based on filing metadata only, document content was unavailable. HCW Biologics filed an amended 10-Q (10-Q/A) t | Aug 14, 2026 |
| HCWB | 8-K | bearish | 8/10 | HCW Biologics filed an 8-K announcing it can no longer rely on its Q1 2026 financial statements due to a material missta | Aug 14, 2026 |
| TRIB | 6-K | mixed | 6/10 | Trinity Biotech secured a $7.0M investment from Perceptive Advisors ($2.5M new debt, $4.5M capitalized interest) via a c | Aug 14, 2026 |
| JSPR | PRESS-RELEASE | neutral | 5/10 | Jasper Therapeutics reported Q2 2026 EPS of -$0.10, a 94.3% beat vs the -$1.74 year-ago loss, but this is largely a mech | Aug 14, 2026 |
| TOMZ | 8-K | mixed | 6/10 | TOMI Environmental Solutions reported Q2 2026 revenue of $2.25M (+118% YoY), significantly beating consensus, with GAAP | Aug 14, 2026 |
| SKYE | 8-K | mixed | 7/10 | Skye Bioscience (SKYE) entered into a definitive transaction agreement to acquire Redx Pharma Limited via a scheme of ar | Aug 14, 2026 |
| SKYE | PRESS-RELEASE | bearish | 7/10 | Skye Bioscience announces a reverse merger with private UK biotech Redx Pharma, forming Fibrx Therapeutics focused on fi | Aug 14, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings (ELAB) reported Q2 2026 revenue of approximately $1.31M, up from $0 in the prior-year period and 92% seque | Aug 14, 2026 |
| DYAI | 8-K | bearish | 6/10 | DYAI completed a two-part capital raise: a registered direct offering of common stock at $0.795/share under an existing | Aug 14, 2026 |
| SLXN | 8-K | bearish | 6/10 | Silexion Therapeutics reported Q2 2026 financial results, highlighting the transition of its lead candidate SIL204 into | Aug 14, 2026 |
| CNTN | PRESS-RELEASE | neutral | 4/10 | Canton Strategic Holdings reported its first-ever operating revenue of $1.5M for Q2 2026, driven by its Canton Network S | Aug 14, 2026 |
| APVO | 8-K | mixed | 5/10 | Aptevo Therapeutics reported Q2 2026 financial results and a business update, highlighting strong clinical data for lead | Aug 14, 2026 |
| OTLK | 8-K | bearish | 6/10 | Outlook Therapeutics reported Q3 FY2026 results with net loss of $20.3M ($0.15 GAAP EPS, $0.09 adjusted) and revenue of | Aug 14, 2026 |
| HELP | 6-K | neutral | 5/10 | Helus Pharma (HELP) reported Q1 FY2027 financial results with a net loss of $47.8M, widening from $24.6M in the prior-ye | Aug 14, 2026 |
| LTRN | 8-K | mixed | 6/10 | Lantern Pharma reported Q2 2026 operating loss of $3.5M ($0.28/share), beating consensus of $0.38/share by 26.3%, driven | Aug 14, 2026 |
| REPL | 8-K | bullish | 7/10 | Replimune reported fiscal Q1 2027 results with an in-line net loss of $69.8M ($-0.72 EPS), but the headline is the FDA a | Aug 14, 2026 |